SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 80.06 |
| Enterprise Value ($M) | 102.95 |
| Book Value ($M) | 24.08 |
| Book Value / Share | 1.71 |
| Price / Book | 3.32 |
| NCAV ($M) | -18.91 |
| NCAV / Share | -1.34 |
| Price / NCAV | -4.23 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.57 |
| Return on Assets (ROA) | -1.09 |
| Return on Equity (ROE) | -1.80 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.75 |
| Current Ratio | 0.75 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 31.90 |
| Assets | 74.89 |
| Liabilities | 50.81 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 71,500 | 222,741 | 32.10 | |
| 55,221 | 229,916 | 24.02 | |
| 61,739 | 183,816 | 33.59 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ALBT – Avalon GloboCare Corp. | ALDX – Aldeyra Therapeutics, Inc. |
| ALGS – Aligos Therapeutics, Inc. | ALVR – AlloVir, Inc. |
| ALZN – Alzamend Neuro, Inc. |
Financial data and stock pages provided by
Fintel.io